ImmuCell Operating Income from 2010 to 2024

ICCC Stock

USD 3.70 0.04 1.07%

ImmuCell's Operating Income is decreasing over the years with slightly volatile fluctuation. Overall, Operating Income is projected to go to about -5.5 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit ImmuCell generates from its operations. View All Fundamentals

Operating Income

First Reported

1989-03-31

Previous Quarter

-1.4 M

Current Value

-574.9 M

Quarterly Volatility

49.5 M

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check ImmuCell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuCell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Interest Expense of 422.5 K or Total Revenue of 18.3 M, as well as many indicators such as Price To Sales Ratio of 1.7, Dividend Yield of 0.0 or PTB Ratio of 1.79. ImmuCell financial statements analysis is a perfect complement when working with ImmuCell Valuation or Volatility modules.

Check out the analysis of ImmuCell Correlation against competitors.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

Latest ImmuCell's Operating Income Growth Pattern

Below is the plot of the Operating Income of ImmuCell over the last few years. Operating Income is the amount of profit realized from ImmuCell operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ImmuCell is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. ImmuCell's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImmuCell's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

ImmuCell Operating Income Regression Statistics

	Arithmetic Mean	(1,215,803)
	Geometric Mean	843,836
	Coefficient Of Variation	(173.66)
	Mean Deviation	1,499,210
	Median	(900,000)
	Standard Deviation	2,111,326
	Sample Variance	4.5T
	Range	7.9M
	R-Value	(0.73)
	Mean Square Error	2.3T
	R-Squared	0.53
	Significance	0
	Slope	(343,164)
	Total Sum of Squares	62.4T

ImmuCell Operating Income History

	2024	-5.5 M
	2023	-5.7 M
	2022	-2.3 M
	2021	-2.2 M
	2020	-1.4 M
	2019	-954 K
	2018	-1.4 M

Other Fundumenentals of ImmuCell

Non Operating Income Net Other

ImmuCell Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.63	-0.61	0.95	0.94	0.66	0.82	0.38	0.61	0.9	0.96	0.95	0.58	0.83	-0.59	0.58	0.96	0.91	0.87	-0.92	0.8	0.77	0.78	0.82
Total Stockholder Equity	0.98		0.45	-0.46	0.92	0.85	0.77	0.7	0.45	0.61	0.9	0.9	0.94	0.42	0.8	-0.51	0.42	0.9	0.92	0.82	-0.92	0.77	0.7	0.77	0.75
Net Debt	0.63	0.45		-0.83	0.58	0.85	-0.02	0.84	-0.03	0.34	0.45	0.76	0.56	0.86	0.51	-0.57	0.86	0.74	0.46	0.65	-0.49	0.55	0.64	0.41	0.65
Retained Earnings	-0.61	-0.46	-0.83		-0.63	-0.78	-0.17	-0.85	0.14	-0.19	-0.53	-0.65	-0.58	-0.89	-0.65	0.67	-0.89	-0.64	-0.54	-0.75	0.42	-0.57	-0.87	-0.71	-0.87
Net Receivables	0.95	0.92	0.58	-0.63		0.89	0.65	0.78	0.27	0.56	0.85	0.89	0.9	0.53	0.78	-0.63	0.53	0.9	0.85	0.86	-0.83	0.72	0.81	0.84	0.84
Total Liab	0.94	0.85	0.85	-0.78	0.89		0.45	0.91	0.24	0.55	0.8	0.97	0.88	0.76	0.78	-0.65	0.76	0.96	0.81	0.87	-0.83	0.77	0.82	0.72	0.85
Total Current Assets	0.66	0.77	-0.02	-0.17	0.65	0.45		0.31	0.33	0.49	0.77	0.47	0.64	0.16	0.51	-0.1	0.16	0.47	0.75	0.48	-0.66	0.45	0.58	0.72	0.59
Short Term Debt	0.82	0.7	0.84	-0.85	0.78	0.91	0.31		0.11	0.32	0.71	0.86	0.84	0.75	0.82	-0.56	0.75	0.84	0.73	0.92	-0.68	0.86	0.8	0.68	0.84
Intangible Assets	0.38	0.45	-0.03	0.14	0.27	0.24	0.33	0.11		0.71	0.39	0.36	0.33	-0.19	0.32	-0.08	-0.19	0.39	0.43	0.17	-0.69	0.31	-0.06	0.01	-0.02
Accounts Payable	0.61	0.61	0.34	-0.19	0.56	0.55	0.49	0.32	0.71		0.52	0.55	0.43	0.31	0.25	-0.21	0.31	0.55	0.52	0.27	-0.81	0.25	0.31	0.26	0.31
Common Stock	0.9	0.9	0.45	-0.53	0.85	0.8	0.77	0.71	0.39	0.52		0.83	0.89	0.45	0.81	-0.54	0.45	0.83	0.99	0.8	-0.84	0.82	0.8	0.82	0.83
Long Term Debt	0.96	0.9	0.76	-0.65	0.89	0.97	0.47	0.86	0.36	0.55	0.83		0.91	0.62	0.81	-0.65	0.62	1.0	0.85	0.86	-0.87	0.8	0.73	0.68	0.77
Treasury Stock	0.95	0.94	0.56	-0.58	0.9	0.88	0.64	0.84	0.33	0.43	0.89	0.91		0.49	0.93	-0.51	0.49	0.91	0.91	0.95	-0.86	0.9	0.73	0.76	0.8
Property Plant Equipment	0.58	0.42	0.86	-0.89	0.53	0.76	0.16	0.75	-0.19	0.31	0.45	0.62	0.49		0.46	-0.54	1.0	0.58	0.44	0.6	-0.4	0.45	0.76	0.56	0.75
Current Deferred Revenue	0.83	0.8	0.51	-0.65	0.78	0.78	0.51	0.82	0.32	0.25	0.81	0.81	0.93	0.46		-0.57	0.46	0.82	0.84	0.95	-0.73	0.92	0.71	0.74	0.78
Short Term Investments	-0.59	-0.51	-0.57	0.67	-0.63	-0.65	-0.1	-0.56	-0.08	-0.21	-0.54	-0.65	-0.51	-0.54	-0.57		-0.54	-0.67	-0.56	-0.58	0.41	-0.47	-0.64	-0.61	-0.64
Net Tangible Assets	0.58	0.42	0.86	-0.89	0.53	0.76	0.16	0.75	-0.19	0.31	0.45	0.62	0.49	1.0	0.46	-0.54		0.58	0.43	0.6	-0.4	0.45	0.76	0.56	0.75
Long Term Debt Total	0.96	0.9	0.74	-0.64	0.9	0.96	0.47	0.84	0.39	0.55	0.83	1.0	0.91	0.58	0.82	-0.67	0.58		0.86	0.85	-0.88	0.8	0.72	0.68	0.76
Capital Surpluse	0.91	0.92	0.46	-0.54	0.85	0.81	0.75	0.73	0.43	0.52	0.99	0.85	0.91	0.44	0.84	-0.56	0.43	0.86		0.83	-0.86	0.84	0.79	0.81	0.82
Deferred Long Term Liab	0.87	0.82	0.65	-0.75	0.86	0.87	0.48	0.92	0.17	0.27	0.8	0.86	0.95	0.6	0.95	-0.58	0.6	0.85	0.83		-0.73	0.91	0.79	0.78	0.85
Long Term Investments	-0.92	-0.92	-0.49	0.42	-0.83	-0.83	-0.66	-0.68	-0.69	-0.81	-0.84	-0.87	-0.86	-0.4	-0.73	0.41	-0.4	-0.88	-0.86	-0.73		-0.73	-0.57	-0.57	-0.62
Short Long Term Debt	0.8	0.77	0.55	-0.57	0.72	0.77	0.45	0.86	0.31	0.25	0.82	0.8	0.9	0.45	0.92	-0.47	0.45	0.8	0.84	0.91	-0.73		0.64	0.62	0.71
Net Invested Capital	0.77	0.7	0.64	-0.87	0.81	0.82	0.58	0.8	-0.06	0.31	0.8	0.73	0.73	0.76	0.71	-0.64	0.76	0.72	0.79	0.79	-0.57	0.64		0.94	0.99
Net Working Capital	0.78	0.77	0.41	-0.71	0.84	0.72	0.72	0.68	0.01	0.26	0.82	0.68	0.76	0.56	0.74	-0.61	0.56	0.68	0.81	0.78	-0.57	0.62	0.94		0.95
Capital Stock	0.82	0.75	0.65	-0.87	0.84	0.85	0.59	0.84	-0.02	0.31	0.83	0.77	0.8	0.75	0.78	-0.64	0.75	0.76	0.82	0.85	-0.62	0.71	0.99	0.95

Click cells to compare fundamentals

About ImmuCell Financial Statements

ImmuCell stakeholders use historical fundamental indicators, such as ImmuCell's Operating Income, to determine how well the company is positioned to perform in the future. Although ImmuCell investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImmuCell's assets and liabilities are reflected in the revenues and expenses on ImmuCell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImmuCell. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-5.7 M	-5.5 M
Non Operating Income Net Other	313.3 K	329 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:

How To Invest In ImmuCell

Details

Is ImmuCell Stock a good investment?

Details

What is ImmuCell's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of ImmuCell Correlation against competitors.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(0.49)

Revenue Per Share

2.991

Quarterly Revenue Growth

0.549

Return On Assets

(0.05)

The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ImmuCell Operating Income from 2010 to 2024

Latest ImmuCell's Operating Income Growth Pattern

ImmuCell Operating Income Regression Statistics

ImmuCell Operating Income History

Other Fundumenentals of ImmuCell

ImmuCell Operating Income component correlations

About ImmuCell Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY